Displaying drugs 10176 - 10200 of 12433 in total
PS386113
PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Investigational
Matched Description: … PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders …
Mepiprazole
Mepiprazole is a minor tranquilizer with a phenylpiperazine structure. It is a pyrazolyl-alkyl-piperazine derivative. Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons .
Mepiprazole is marketed in Spain for the treatment of anxiety neuroses.
It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and...
Experimental
Matched Description: … Mepiprazole is marketed in Spain for the treatment of anxiety neuroses. ... Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons [A7816]. ... Clinical studies of mepiprazole including patients with irritable bowel syndrome (IBS) were conducted …
Aptazapine
Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of serotonin or norepinephrine. Although Aptazapine reached clinical trials, it...
Experimental
Matched Description: … effectively than mianserin, antagonised 5-HT2 receptors, agonised H1 receptors, and did not affect reuptake of …
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
Matched Description: … of coronary artery disease. ... , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment ... TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical …
ICA-105665
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
Matched Description: … of activity in models of epilepsy. ... ICA-105665 is a novel small molecule compound for the treatment of epilepsy. ... In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain. …
8-chlorotheophylline
8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar to caffeine. Its main use is in combination with Diphenhydramine as the antiemetic drug Dimenhydrinate. The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous...
Experimental
Matched Description: … 8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar ... anti-histamine activity in the central nervous system.
8-chlorotheophylline produces a number of ... Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the …
Sitimagene ceradenovec
Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy/chemotherapy. It is being developed by Ark Therapeutics.
Investigational
Matched Description: … Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high ... grade glioma, a type of malignant brain tumour, given in addition to standard surgery and radiotherapy …
Cilansetron
Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Investigational
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over ... The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
SC12267
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational
Matched Description: … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating ... cells, especially of lymphocytes, which are important for the immune response. ... ) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. …
Platelet Lysate
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
Matched Description: … [A220188] It is extracted through lysis of the plasma membrane of platelets. ... Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular ... Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses …
Etrolizumab
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of intestinal-homing lymphocytes.[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some...
Investigational
Matched Description: … in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal leukoencephalopathy ... [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted ... gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory ... protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG. …
BMS-919373
BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).
Investigational
Matched Description: … BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on ... the Electrical Activity of the Heart Using Pacemakers). …
Tenocyclidine
Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.
Experimental
Illicit
Investigational
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Description: … of an earlier onset of action compared to antidepressants already on the market. ... a desired "triple-mode-of-action". ... with a new, unique drug profile expected to yield important benefits compared to existing treatments of …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … of atherosclerosis. ... to sites of inflammation. ... Plozalizumab has been investigated for the treatment of Atherosclerosis. …
Go-6976
An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]
Investigational
Matched Description: … An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007] …
ATL1101
ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis.
Investigational
Matched Description: … ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis ... a protein involved in the regulation of cell overgrowth in psoriasis. ... ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, …
Ciraparantag
Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).
Investigational
Matched Description: … Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban). ... Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single …
AZD0947
AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder. As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.
Investigational
Matched Description: … As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared ... AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive …
Lesopitron
Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.
Investigational
LGD2941
LGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
Investigational
Paliroden
Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It is indicated for use in Alzheimer's Disease and Parkinson’s.
Investigational
Matched Description: … Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature ... Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous …
Displaying drugs 10176 - 10200 of 12433 in total